NASDAQ:DCTH

Delcath Systems Stock Insider Trading

Healthcare > Medical - Specialties

Buy DCTH

*Your capital is at risk

$10.33

-0.200 (-1.90%)

At Close: Jun 03, 2026

Delcath Systems Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 11.02M and sold 77.82K DCTH shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	11.02M shares
● Sell	77.82K shares
89% Buy Activity Moderate Positive Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 13, 2026 Buy	Stock Option (right to buy) A-Award	Sylvester John Richard Director	Director	22 500 Value: $261.2K
May 13, 2026 Buy	Stock Option (right to buy) A-Award	Martell Bridget A Director	Director	22 500 Value: $261.2K
May 13, 2026 Buy	Stock Option (right to buy) A-Award	Czerepak Elizabeth Director	Director	22 500 Value: $261.2K
May 13, 2026 Buy	Stock Option (right to buy) A-Award	Salamon Steven A J Director	Director	22 500 Value: $261.2K
May 13, 2026 Buy	Stock Option (right to buy) A-Award	Aharon Gil Director	Director	22 500 Value: $261.2K
Mar 06, 2026 Buy	Common Stock P-Purchase	Pennell Sandra Chief Financial Officer	C-Suite Officer	5 533 Value: $50.0K
Mar 02, 2026 Buy	Common Stock P-Purchase	Michel Gerard J Chief Executive Officer	CEO / President	11 200 Value: $100.3K
Feb 17, 2026 Buy	Stock Option (Right to Buy) A-Award	Vukovic Vojo Chief Medical Officer	Officer	56 500 Value: $531.1K
Feb 17, 2026 Buy	Restricted Stock Units A-Award	Pennell Sandra Chief Financial Officer	C-Suite Officer	28 250 Value: $265.6K
Feb 17, 2026 Buy	Stock Option (Right to Buy) A-Award	Pennell Sandra Chief Financial Officer	C-Suite Officer	56 500 Value: $531.1K
Feb 17, 2026 Buy	Restricted Stock Units A-Award	Muir Kevin Gm Interventional Oncology	Officer	28 250 Value: $265.6K
Feb 17, 2026 Buy	Stock Option (Right to Buy) A-Award	Muir Kevin Gm Interventional Oncology	Officer	56 500 Value: $531.1K
Feb 17, 2026 Buy	Restricted Stock Units A-Award	Hoffman David L. Gen'l Counsel, Cco & Secy	Officer	28 250 Value: $265.6K
Feb 17, 2026 Buy	Stock Option (Right to Buy) A-Award	Hoffman David L. Gen'l Counsel, Cco & Secy	Officer	56 500 Value: $531.1K
Feb 17, 2026 Buy	Restricted Stock Units A-Award	Vukovic Vojo Chief Medical Officer	Officer	28 250 Value: $265.6K
Feb 17, 2026 Buy	Stock Option (Right to Buy) A-Award	Rook Martha S. Chief Operating Officer	C-Suite Officer	56 500 Value: $531.1K
Feb 17, 2026 Buy	Restricted Stock Units A-Award	Rook Martha S. Chief Operating Officer	C-Suite Officer	28 250 Value: $265.6K
Feb 17, 2026 Buy	Stock Option (Right to Buy) A-Award	Michel Gerard J Chief Executive Officer	CEO / President	195 000 Value: $1.83M
Feb 17, 2026 Buy	Restricted Stock Units A-Award	Michel Gerard J Chief Executive Officer	CEO / President	97 500 Value: $916.5K
Nov 21, 2025 Buy	Common Stock P-Purchase	Sylvester John Richard Director	Director	4 386 Value: $39.0K
Nov 11, 2025 Buy	Common Stock P-Purchase	Michel Gerard J Chief Executive Officer	CEO / President	11 500 Value: $98.0K
Jun 12, 2025 Buy	Common Stock M-Exempt	Vukovic Vojo Chief Medical Officer	Officer	42 000 Value: $200.8K
Jun 12, 2025 Buy	Employee Stock Option (Right to Buy) M-Exempt	Vukovic Vojo Chief Medical Officer	Officer	42 000 Value: $200.8K
Jun 12, 2025 Buy	Employee Stock Option (Right to Buy) M-Exempt	Vukovic Vojo Chief Medical Officer	Officer	42 000 Value: $200.8K
Jun 12, 2025 Buy	Common Stock M-Exempt	Vukovic Vojo Chief Medical Officer	Officer	42 000 Value: $200.8K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT DELCATH SYSTEMS, INC.

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS cli...

Read Full Profile Here